$0.44 EPS Expected for Endo International PLC (ENDP) This Quarter

Wall Street analysts forecast that Endo International PLC (NASDAQ:ENDP) (TSE:ENL) will post $0.44 earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Six analysts have provided estimates for Endo International’s earnings. The lowest EPS estimate is $0.36 and the highest is $0.66. Endo International reported earnings of $0.67 per share during the same quarter last year, which would indicate a negative year-over-year growth rate of 34.3%. The business is scheduled to report its next quarterly earnings report on Tuesday, May 14th.

On average, analysts expect that Endo International will report full-year earnings of $2.17 per share for the current fiscal year, with EPS estimates ranging from $2.05 to $2.25. For the next fiscal year, analysts anticipate that the firm will post earnings of $2.40 per share, with EPS estimates ranging from $1.78 to $3.12. Zacks’ EPS calculations are a mean average based on a survey of sell-side analysts that follow Endo International.

Endo International (NASDAQ:ENDP) (TSE:ENL) last announced its quarterly earnings results on Thursday, February 28th. The company reported $0.75 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.59 by $0.16. The business had revenue of $786.39 million during the quarter, compared to analysts’ expectations of $744.24 million. Endo International had a negative net margin of 35.00% and a negative return on equity of 337.13%. During the same quarter in the prior year, the company posted $0.77 EPS.

A number of equities analysts have weighed in on the stock. BidaskClub downgraded shares of Endo International from a “hold” rating to a “sell” rating in a research note on Wednesday, January 2nd. Leerink Swann lowered shares of Endo International from an “outperform” rating to a “market perform” rating in a research note on Tuesday, March 5th. Svb Leerink downgraded Endo International from an “outperform” rating to a “market perform” rating in a research note on Tuesday, March 5th. ValuEngine raised shares of Endo International from a “sell” rating to a “hold” rating in a research report on Tuesday, March 12th. Finally, Zacks Investment Research upgraded shares of Endo International from a “hold” rating to a “strong-buy” rating and set a $11.00 price objective on the stock in a research note on Wednesday, January 9th. Sixteen research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. The company currently has an average rating of “Hold” and an average target price of $15.44.

Several hedge funds have recently made changes to their positions in the company. LS Investment Advisors LLC purchased a new stake in shares of Endo International in the 4th quarter worth $59,000. Oregon Public Employees Retirement Fund bought a new position in shares of Endo International during the 4th quarter worth $76,000. First Quadrant L P CA bought a new position in shares of Endo International during the 4th quarter worth $92,000. Neuburgh Advisers LLC increased its stake in shares of Endo International by 13.9% during the fourth quarter. Neuburgh Advisers LLC now owns 24,860 shares of the company’s stock valued at $181,000 after buying an additional 3,036 shares during the period. Finally, Neuberger Berman Group LLC purchased a new position in shares of Endo International during the third quarter valued at $202,000. Hedge funds and other institutional investors own 95.69% of the company’s stock.

Shares of NASDAQ:ENDP traded up $0.17 during trading on Monday, hitting $8.37. The stock had a trading volume of 1,756,568 shares, compared to its average volume of 3,171,826. The firm has a market capitalization of $1.84 billion, a P/E ratio of 2.90 and a beta of 1.17. Endo International has a 12 month low of $5.31 and a 12 month high of $18.50.

Endo International Company Profile

Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States, Canada, and internationally. The company operates through three segments: U.S. Generic Pharmaceuticals, U.S. Branded Pharmaceuticals, and International Pharmaceuticals.

Recommended Story: How mutual funds make money

Get a free copy of the Zacks research report on Endo International (ENDP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Endo International (NASDAQ:ENDP)

Receive News & Ratings for Endo International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International and related companies with MarketBeat.com's FREE daily email newsletter.